BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Company News  |  Other News

Theratechnologies endocrine/metabolic, pulmonary news

Theratechnologies will restructure and reduce headcount by about 40 (60%) to about 27 and discontinue development of tesamorelin for muscle wasting in chronic obstructive pulmonary disease (COPD). According to Theratechnologies, the compound was "still in early stages" of enrollment in a Phase II trial for COPD. The company made the decision with the goal of becoming profitable in...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >